Unverricht–Lundborg disease
Unverricht–Lundborg disease (ULD), also known as Baltic myoclonus, is a type of progressive myoclonus epilepsy (PME). It is a rare, inherited neurodegenerative disorder characterized by myoclonus, epileptic seizures, and a progressive decline in motor skills. The disease was first described by Heinrich Unverricht in 1891 and later by Herman Bernhard Lundborg in 1901.
Symptoms[edit]
The primary symptoms of Unverricht–Lundborg disease include:
- Myoclonus: Sudden, involuntary muscle jerks that can be triggered by physical activity, stress, or sensory stimuli.
- Epileptic seizures: Generalized tonic-clonic seizures are common.
- Ataxia: Loss of coordination and balance.
- Dysarthria: Difficulty in articulating words due to muscle weakness.
- Cognitive decline: Progressive deterioration in cognitive functions.
Genetics[edit]
Unverricht–Lundborg disease is caused by mutations in the CSTB gene, which encodes the cystatin B protein. This gene is located on chromosome 21. The disease is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to develop the disorder.
Diagnosis[edit]
Diagnosis of Unverricht–Lundborg disease typically involves:
- Electroencephalography (EEG): To detect abnormal brain activity.
- Genetic testing: To identify mutations in the CSTB gene.
- Magnetic resonance imaging (MRI): To observe any structural abnormalities in the brain.
Treatment[edit]
There is no cure for Unverricht–Lundborg disease, but treatment focuses on managing symptoms. Common treatments include:
- Antiepileptic drugs: Such as valproate, clonazepam, and levetiracetam to control seizures and myoclonus.
- Physical therapy: To improve motor skills and coordination.
- Occupational therapy: To assist with daily activities and improve quality of life.
Prognosis[edit]
The progression of Unverricht–Lundborg disease varies among individuals. While the disease is progressive, many patients can live into adulthood with appropriate management of symptoms. However, the quality of life may be significantly affected due to the severity of myoclonus and seizures.
Related Pages[edit]
- Progressive myoclonus epilepsy
- Myoclonus
- Epileptic seizure
- CSTB gene
- Autosomal recessive inheritance
See Also[edit]
References[edit]
External Links[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian